Updated to include the newest drugs and those currently in development, this Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agentsatheir mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised. A companion website includes the fully searchable text and an image bank.Chemical genetics: ligand-based discovery of gene function. ... Cancer Res 2009 ;69:4059a4066. 24. ... Cancer Cell 2003;3:233a245. ... A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. ... Natural products as sources of new drugs over the last 25 years. ... Use of peptide synthesis to probe viral antigens for epitopes to resolution of a single amino acid.
|Title||:||Cancer Chemotherapy and Biotherapy|
|Author||:||Bruce A. Chabner, Dan L. Longo|
|Publisher||:||Lippincott Williams & Wilkins - 2011-12-07|